ClinicalTrials.gg
CompletedNCT01426269Updated Aug 1, 2022Results posted

Evaluation of Relapse, Efficacy and Safety of Long-term Treatment With Oracea® vs Placebo

A Phase 4 interventional study of Doxycycline and Metronidazole in Rosacea, sponsored by Galderma R&D. Completed at 11 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-08-01.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
235
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing doxycycline in Rosacea — none open to participants now, 1 under way, none of them phase 3. Doxycycline · Rosacea.

Enrollment
3rd of 12
235 · median 150
Started
2011
with 1 other
Phase 4
6 of 12
none open now
Registered
6th of 12
by date
Lead sponsor
4 of 12
Galderma R&D

Among the 12 studies testing doxycycline in Rosacea, this one is the 3rd largest by enrollment, is one of 2 that started in 2011, is one of 6 in phase 4, and was the 6th registered.

Rosacea

233 studies on the registry are indexed under Rosacea; 23 are open to participants now.

Browse Rosacea studies →

Open to participants now

None of the 12 studies testing doxycycline in Rosacea is open now. The open studies under Rosacea, anywhere →

Where they have run

About doxycycline

Doxycycline: first FDA approval 1967 (VIBRAMYCIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 17 Rosacea studies recruiting now, 9 (53%) set no upper age limit and 7 (41%) stop at 75 or younger; 1 takes children under 18; 8 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing doxycycline in Rosacea as a file.
02

Study summary

The purpose of this study is to assess relapse, efficacy and safety in subjects with rosacea during long-term treatment with either Oracea® or placebo, after an initial 12-week regimen of Oracea® and MetroGel® 1%.

Read the detailed description

Adult subjects with moderate to severe papulopustular rosacea will receive Oracea® and MetroGel® 1% once daily during phase 1 (baseline to week 12) of the study. Subjects will be eligible to enter phase 2 of the study based upon improvements in the Investigator's Global Assessment (IGA) score. During phase 2, subjects will receive either Oracea® or placebo once daily for up to an additional 40 weeks. Subjects who relapse during phase 2 will be discontinued from the study.

03

Conditions studied

  • Rosacea

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is male or female aged 18 to 80 years inclusive.
  • Subject with papulopustular rosacea (11 to 40 papules or pustules) and an IGA of moderate or severe.
  • For subjects using medications to treat a concurrent medical condition, type and dose must have been stable for at least 90 days prior to study entry.

Exclusion criteria

Exclusion Criteria:

  • Female subjects who are pregnant, nursing or planning a pregnancy during the study.
  • Subject has any other active dermatological condition on the face that may interfere with the conduct of the study.
  • Subject uses or has recently used any medication which may interfere with the absorption, distribution, or elimination of study medications, or may interfere with the assessments of efficacy or safety of the study medications.
  • Subject has a known allergy to any of the components of the study products, and/or a known to tetracyclines or metronidazole.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
235 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Subjects will receive placebo during phase 2 (week 12 - week 52)

    Drug: Placebo

  • Other
    Doxycycline and Metronidazole

    Subjects will receive Oracea® (oral doxycycline 40 mg USP (30 mg immediate release and 10 mg delayed release beads)) and MetroGel® 1% (topical metronidazole) during phase 1 (baseline to week 12)

    Drug: Doxycycline · Drug: Metronidazole

  • Active comparator
    Doxycycline

    Subjects will receive Oracea® (oral doxycycline 40 mg USP (30 mg immediate release and 10 mg delayed release beads)) during phase 2 (week 12 - week 52)

    Drug: Doxycycline

Interventions

  • During phase 1 (baseline - week 12): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads)), oral, one capsule daily in the morning During phase 1 (baseline - week 12) and phase 2 (week 12 - week 52): Oracea (doxycycline 40 mg USP (30 mg immediate release \& 10 mg delayed release beads), oral, one capsule daily in the morning

    Also known as: Oracea® Capsules 40 mg

  • During Phase 1: MetroGel 1% (metronidazole 1% gel), topical, apply a thin layer once daily to the affected area

    Also known as: Metrogel 1%

  • DrugPlacebo

    During phase 2 (week 12 - week 52): placebo, oral, one capsule daily in the morning

06

What researchers measure

Primary outcomes

  1. Period 2: Number of Subjects Who Relapsed

    Subjects who relapsed during phase 2 were discontinued. Relapse was defined as meeting any one of the following criteria: * A return to the baseline lesion count * A return to the baseline IGA score * The investigator determines that a change in rosacea treatment is warranted due to the subject's clinical condition. The numbers reported here are accumulative numbers for each arm.

    Time frame: Period 2 (40 weeks)

Secondary outcomes

  1. Period 2: Investigator's Global Assessment Success

    The evaluator (investigator) assessed the severity of rosacea at baseline and each postbaseline visit using a 5 point Investigator's Global Assessment scale. Subjects scores were then dichotomized into success (clear or near clear score) or failure (mild, moderate, or severe score).

    Time frame: Period 2 (40 weeks)

  2. Period 2: Clinician's Erythema Assessment

    The evaluator (investigator) assessed the severity of erythema at baseline and each postbaseline visit using a total erythema score. The erythema of 5 areas of the face (forehead, chin, nose, right cheek, left cheek) was scored using a 5 point Clinician's Erythema Assessment scale (0 = none, 1 = mild, 2 = moderate, 3 = significant, 4 = severe). The total of the 5 individual erythema scores scores was the total erythema score.

    Time frame: Period 2 (40 Weeks)

  3. Period 2: Inflammatory Lesion Count

    The evaluator (investigator or a designee) performed lesion counts at each postbaseline visit.

    Time frame: Period 2 (40 Weeks)

Other outcomes

  1. Period 1: Tolerability (Scaling)

    Scaling, dryness, and stinging/burning were graded at baseline and weeks 4, 8, and 12 for subjects taking oral doxycycline and topical metronidazole.

    Time frame: Period 1 (12 Weeks)

  2. Period 1: Tolerability (Stinging/Burning)

    Scaling, dryness, and stinging/burning were graded at baseline and weeks 4, 8, and 12 for subjects taking oral doxycycline and topical metronidazole.

    Time frame: Period 1 (12 Weeks)

  3. Period 1: Tolerability (Dryness)

    Scaling, dryness, and stinging/burning were graded at baseline and weeks 4, 8, and 12 for subjects taking oral doxycycline and topical metronidazole.

    Time frame: Period 1 (12 Weeks)

07

Results

Posted Aug 4, 2014

Participant flow

Period 1: 12 Weeks
Participant flow — Period 1: 12 Weeks
MilestoneDoxycycline and Metronidazole RegimenOral DoxycyclinePlacebo
Started23500
Completed18000
Not completed5500
Withdrew: Adverse event500
Withdrew: Withdrawal by subject2200
Withdrew: Protocol violation500
Withdrew: Lost to follow-up2200
Withdrew: Pregnancy100
Eligibility for Period 2, Randomization
Participant flow — Eligibility for Period 2, Randomization
MilestoneDoxycycline and Metronidazole RegimenOral DoxycyclinePlacebo
Started18000
Completed13000
Not completed5000
Withdrew: Did not qualify4200
Withdrew: Qualified, opted out800
Period 2: 40 Weeks
Participant flow — Period 2: 40 Weeks
MilestoneDoxycycline and Metronidazole RegimenOral DoxycyclinePlacebo
Started06565
Completed02718
Not completed03847
Withdrew: Adverse event012
Withdrew: Withdrawal by subject0911
Withdrew: Protocol violation055
Withdrew: Lost to follow-up086
Withdrew: Site closed065
Withdrew: Relapsed0918

Outcome measures

PrimaryPeriod 2: Number of Subjects Who Relapsed

Subjects who relapsed during phase 2 were discontinued. Relapse was defined as meeting any one of the following criteria: * A return to the baseline lesion count * A return to the baseline IGA score * The investigator determines that a change in rosacea treatment is warranted due to the subject's clinical condition. The numbers reported here are accumulative numbers for each arm.

Time frame:
Period 2 (40 weeks)
Reported as:
Number · participants
Period 2: Number of Subjects Who Relapsed
participantsOral DoxycyclinePlacebo
Week 4410
Week 8814
Week 12916
Week 16916
Week 20916
Week 24917
Week 28918
Week 32918
Week 36918
Week 40918
SecondaryPeriod 2: Investigator's Global Assessment Success

The evaluator (investigator) assessed the severity of rosacea at baseline and each postbaseline visit using a 5 point Investigator's Global Assessment scale. Subjects scores were then dichotomized into success (clear or near clear score) or failure (mild, moderate, or severe score).

Time frame:
Period 2 (40 weeks)
Reported as:
Number · participants
Period 2: Investigator's Global Assessment Success
participantsOral DoxycyclinePlacebo
Week 44438
Week 83633
Week 123337
Week 163834
Week 203533
Week 243632
Week 283935
Week 323934
Week 364033
Week 404133
SecondaryPeriod 2: Clinician's Erythema Assessment

The evaluator (investigator) assessed the severity of erythema at baseline and each postbaseline visit using a total erythema score. The erythema of 5 areas of the face (forehead, chin, nose, right cheek, left cheek) was scored using a 5 point Clinician's Erythema Assessment scale (0 = none, 1 = mild, 2 = moderate, 3 = significant, 4 = severe). The total of the 5 individual erythema scores scores was the total erythema score.

Time frame:
Period 2 (40 Weeks)
Reported as:
Mean · units on a scale
Period 2: Clinician's Erythema Assessment
units on a scaleOral DoxycyclinePlacebo
Week 45.0 ± 3.15.6 ± 3.8
Week 84.9 ± 3.55.8 ± 3.9
Week 124.7 ± 3.45.3 ± 4.3
Week 164.7 ± 3.45.2 ± 3.8
Week 204.3 ± 3.45.5 ± 3.8
Week 244.4 ± 3.55.3 ± 3.8
Week 284.3 ± 3.55.3 ± 3.8
Week 324.2 ± 3.65.3 ± 3.9
Week 364.4 ± 3.65.3 ± 3.8
Week 404.4 ± 3.55.3 ± 3.9
SecondaryPeriod 2: Inflammatory Lesion Count

The evaluator (investigator or a designee) performed lesion counts at each postbaseline visit.

Time frame:
Period 2 (40 Weeks)
Reported as:
Mean · lesions
Period 2: Inflammatory Lesion Count
lesionsOral DoxycyclinePlacebo
Week 42.8 ± 4.55.8 ± 8.7
Week 83.1 ± 4.14.3 ± 6.0
Week 123.0 ± 4.21.9 ± 2.7
Week 162.4 ± 4.02.3 ± 2.6
Week 202.1 ± 2.22.6 ± 3.1
Week 242.2 ± 2.72.9 ± 3.9
Week 282.2 ± 2.82.9 ± 4.0
Week 322.2 ± 3.02.4 ± 3.3
Week 362.5 ± 3.12.2 ± 3.0
Week 402.1 ± 2.61.6 ± 1.9
Other pre-specifiedPeriod 1: Tolerability (Scaling)

Scaling, dryness, and stinging/burning were graded at baseline and weeks 4, 8, and 12 for subjects taking oral doxycycline and topical metronidazole.

Time frame:
Period 1 (12 Weeks)
Reported as:
Number · participants
Period 1: Tolerability (Scaling)
participantsBaselineWeek 4Week 8Week 12
None103136139143
Mild85584423
Moderate4424112
Severe3000
Missing0174167
Other pre-specifiedPeriod 1: Tolerability (Stinging/Burning)

Scaling, dryness, and stinging/burning were graded at baseline and weeks 4, 8, and 12 for subjects taking oral doxycycline and topical metronidazole.

Time frame:
Period 1 (12 Weeks)
Reported as:
Number · participants
Period 1: Tolerability (Stinging/Burning)
participantsBaselineWeek 4Week 8Week 12
None90135139143
Mild71514419
Moderate6031116
Severe14100
Missing0174167
Other pre-specifiedPeriod 1: Tolerability (Dryness)

Scaling, dryness, and stinging/burning were graded at baseline and weeks 4, 8, and 12 for subjects taking oral doxycycline and topical metronidazole.

Time frame:
Period 1 (12 Weeks)
Reported as:
Number · participants
Period 1: Tolerability (Dryness)
participantsBaselineWeek 4Week 8Week 12
None76106120125
Mild89786137
Moderate6032136
Severe10200
Missing0174167

Adverse events

Collected over Period 1 (12 weeks of treatment with oral doxycycline and topical metronidazole) and Period 2 (40 weeks of treatment with oral doxycycline or placebo). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Period 1: Oral Doxycycline and Topical Metronidazole—4/235 (1.7%)9/235 (3.8%)
Period 2: Oral Doxycycline—2/65 (3.1%)6/65 (9.2%)
Period 2: Placebo—2/65 (3.1%)7/65 (10.8%)
Most frequent serious events
Most frequent serious events
EventPeriod 1: Oral Doxycycline and Topical MetronidazolePeriod 2: Oral DoxycyclinePeriod 2: Placebo
CellulitisInfections and infestations0/2351/650/65
Infected bitesInfections and infestations0/2351/650/65
GastritisGastrointestinal disorders0/2351/650/65
PresyncopeNervous system disorders0/2351/650/65
Grand mal convulsionNervous system disorders0/2350/651/65
Endometrial cancer stage 1Neoplasms benign, malignant and unspecified (incl cysts and polyps)0/2350/651/65
DiverticulitisInfections and infestations1/2350/650/65
Pain in ExtremityMusculoskeletal and connective tissue disorders1/2350/650/65
HeadacheNervous system disorders1/2350/650/65
ThyroidectomySurgical and medical procedures1/2350/650/65
Most frequent other events
Most frequent other events
EventPeriod 1: Oral Doxycycline and Topical MetronidazolePeriod 2: Oral DoxycyclinePeriod 2: Placebo
Upper respiratoryInfections and infestations1/2351/653/65
NauseaGastrointestinal disorders2/2352/650/65
Gastroenteritis viralInfections and infestations1/2352/650/65
SinusitisInfections and infestations4/2351/652/65
Actinic keratosisSkin and subcutaneous tissue disorders1/2350/652/65

Baseline characteristics

The safety population included 235 enrolled subjects. However, Baseline demographics were based on the ITT population which included 230 subjects; 5 subjects were excluded from this population due to consent issues.

Age, Continuous
Age, Continuous(years)Period 1: Oral Doxycycline and Topical Metronidazole
Mean47.4 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)Period 1: Oral Doxycycline and Topical Metronidazole
Female164
Male66
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Period 1: Oral Doxycycline and Topical Metronidazole
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American7
White217
More than one race5
Unknown or Not Reported0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Period 1: Oral Doxycycline and Topical Metronidazole
Hispanic or Latino44
Not Hispanic or Latino186
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Period 1: Oral Doxycycline and Topical Metronidazole
United States230
Skin Type
Skin Type(participants)Period 1: Oral Doxycycline and Topical Metronidazole
Dry40
Normal50
Oily38
Combination102
FItzpatrick Skin Type
FItzpatrick Skin Type(participants)Period 1: Oral Doxycycline and Topical Metronidazole
I16
II93
III64
IV42
V15
VI0
History of Rosacea
History of Rosacea(years)Period 1: Oral Doxycycline and Topical Metronidazole
Mean4.4 ± 7.7

2 further baseline measures are reported on the registry.

08

Study locations

11 sites
  • ATS Clinical Research
    Santa Monica, California 90404, United States
  • Dadeland Dermatology
    Coral Gables, Florida 33134, United States
  • Melissa L. F. Knuckles M.D., P.S.C.
    Corbin, Kentucky 40701, United States
  • Dermatology Specialists Research
    Louisville, Kentucky 40202, United States
  • Melissa L. F. Knuckles M.D., P.S.C.
    Richmond, Kentucky 40475, United States
  • The Maryland Laser, Skin, and Vein Institute, LLC
    Hunt Valley, Maryland 21030, United States
  • Grekin Skin Institute
    Warren, Michigan 48088, United States
  • Hilary Baldwin
    Brooklyn, New York 11201, United States
  • The Center for Dermatology at Linden Oaks
    Rochester, New York 14625, United States
  • Brodell Medical, Inc.
    Warren, Ohio 44483, United States
  • Center for Dermatology and Laser Surgery
    Portland, Oregon 97225, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Jun 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2011
First posted
Aug 31, 2011
Start
Sep 2011
Primary completionActual
Jun 2013
CompletionActual
Jun 2013
Results first posted
Aug 4, 2014
Last update
Aug 1, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01426269
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Aug 31, 2011
Start date
Sep 2011
Primary completion
Jun 2013
Completion
Jun 2013
Results posted
Aug 4, 2014
Last update
Aug 1, 2022

Study contacts

Ronald W Gottschalk, MD
study director · Galderma R&D

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Doxycycline · Metronidazole

Start the discussion